La Jolla Pharmaceutical Company (LJPC) 2010年年度报告「NASDAQ」.pdf

1、Table of ContentsUNITED STATES SECURITIES AND EXCHANGE COMMISSIONWASHINGTON,DC 20549FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934For the fiscal year ended DECEMBER 31,2010OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIESEXCHANGE AC

2、T OF 1934For the transition period from to Commission file number:0-24274LA JOLLA PHARMACEUTICAL COMPANY(Exact name of registrant as specified in its charter)Delaware 33-0361285(State or other jurisdiction(I.R.S.Employerof incorporation or organization)Identification Number)4365 Executive Drive,Suit

3、e 300,San Diego,CA 92121(Address of principal executive offices,including Zip Code)Registrants telephone number,including area code:(858)452-6600Securities registered pursuant to Section 12(b)of the Act:Securities registered pursuant to Section 12(g)of the Act:Common Stock,Par Value$0.0001 per share

4、Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes o No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d)of the Act.Yes o No Indicate by check mark whether the registrant:(1)

5、has filed all reports required to be filed by Section 13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to filesuch reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No oIndic

6、ate by check mark whether the registrant has submitted electronically and posted on its corporate Web site,if any,every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding12 months(or for such shorter period that the registrant was re